Pre-made Larcaviximab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-297

Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Larcaviximab is a chimeric (mouse/human) monoclonal antibody that can be potentially used in the treatment of Ebola Virus Infection.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-297-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody
INN Name Larcaviximab
TargetZaire Ebolavirus GP
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure5ken:CD:GH:NO
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesMapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases
Conditions Approvedna
Conditions ActiveEbola virus infections
Conditions Discontinuedna
Development TechZmapp Technology